Stay updated with breaking news from Thomask Equels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc. today announced the...
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is...
Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions Safety results show Ampligen is generally well tolerated in the treatment of...
OCALA - AIM ImmunoTech Inc. today announced that the first subject has been enrolled at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM's Ampligen with AstraZeneca's...
OCALA - AIM ImmunoTech Inc. today announced that enrollment is open at Erasmus Medical Center in a Phase 1b/2 clinical trial combining AIM's Ampligen with AstraZeneca's anti-PD-L1 immune...